GSK announced a $10.6 billion agreement to acquire Nuvalent, a clinical-stage biopharmaceutical company advancing precision-targeted oncology therapies, on June 9th, 2026. The acquisition will grant GSK the rights to zidesamtinib and neladalkib, two late-stage treatment candidates for non-small cell lung cancer (NSCLC) currently under regulatory review by FDA. According to a company press release announcing the deal, GSK will also acquire the rights to NVL-330, a therapeutic candidate currently in Phase I trials as a treatment for HER2-altered NSCLC.
Zidesamtinib and neladalkib are two potential best-in-class, next-generation, highly selective ROS1 and ALK inhibitors, according to the release. The assets have both received Breakthrough Therapy and Orphan Drug Designations from FDA, and were issued target decision dates of September 18th, 2026, and November 27th, 2026, respectively.
“Today’s acquisition is a multi-product deal, consistent with our approach to acquire assets that have clinically proven targets and meaningfully address an efficacy and/or tolerability gap. The two lead products are potential best-in-class assets that could launch this year if approved by the FDA and offer significant new treatment options to patients with two forms of non-small cell lung cancer,” said Luke Miels, CEO, GSK, in the release. “The acquisition provides GSK with immediate new sales growth opportunities, improving profit contributions from 2027, and a platform in lung cancer for rapid expansion with Ris-Rez, our B7-H3 targeted ADC in Phase III clinical development.”
“Since our founding, we have leveraged our deep expertise in chemistry and structure-based drug design to develop a portfolio of novel, potentially best-in-class kinase inhibitors. Our close collaboration with leading physician-scientists and patient advocates has driven remarkable enrollment, accelerating development and building confidence in the clinical profile of these drugs,” said James Porter, PhD, CEO, Nuvalent, in the release. “We’re excited that GSK has recognised the significant value these programmes can offer patients and shares our vision for practice-changing innovation. GSK’s proven track record, infrastructure, and expertise will support the successful commercialisation of zidesamtinib and neladalkib, as well as accelerate advancement of our broader discovery pipeline.”
Per the terms of the agreement, Nuvalent will be purchased for $124 per share, representing a 40% premium to the last closing price and a 26% premium to the 30-day volume-weighted average price. The acquisition is expected to be accretive to GSK’s sales and core operating profit in 2027 and core earnings per share in 2029, inclusive of synergies and reprioritisation, according to the release.
